2026 FDA Peptide Compounding Watchlist
Follow profile-linked peptide-related FDA compounding signals, filter by status or use case, and jump directly to each research profile.
Last updated: 28 May 2026
This tracker is an editorial summary of public regulatory signals. It is not medical or legal advice, and it does not route care or sales.
20 peptides shown
| Peptide | Common name | FDA signal | Watch status | Confidence | Use cases | MHRA status | TGA status | Last updated | Source |
|---|---|---|---|---|---|---|---|---|---|
| BPC-157 FDA has identified peptide-related safety concerns and scheduled BPC-157-related substances for PCAC discussion. | Body Protection Compound 157 | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High Shifted | RecoveryGI research | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA PCAC notice |
| KPV FDA discusses KPV on its safety-risk page and scheduled KPV-related substances for PCAC review. | Lysine-Proline-Valine | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High Shifted | ImmuneGI researchWound healing | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA PCAC notice |
| TB-500 FDA safety-risk language discusses TB-500, and TB-500-related substances are scheduled for PCAC review. | Thymosin Beta-4 fragment | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High | RecoveryWound healing | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA PCAC notice |
| CJC-1295 FDA safety-risk language identifies concerns around CJC-1295, including limited clinical data and reported adverse events. | Growth hormone releasing hormone analog | FDA safety-risk page | Safety-risk signal | High | Growth hormoneBody composition | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA safety-risk page |
| Ipamorelin FDA lists ipamorelin acetate under 503B Category 2 and discusses peptide-related safety concerns. | Growth hormone secretagogue | 503B Category 2; safety-risk page | Safety-risk signal | High | Growth hormoneRecovery | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA safety-risk page |
| AOD-9604 FDA's safety-risk page discusses AOD-9604 and notes limited safety information and reported serious adverse events. | Modified hGH fragment 176-191 | FDA safety-risk page | Safety-risk signal | High | Weight lossMetabolic | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA safety-risk page |
| Selank FDA's safety-risk page discusses selank acetate and notes limited information about safety issues in humans. | Tuftsin analog | FDA safety-risk page | Safety-risk signal | High | CognitiveStress research | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA safety-risk page |
| Semax FDA discusses semax on its safety-risk page and scheduled semax-related substances for PCAC review. | ACTH fragment analog | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High | CognitiveNeuroprotection | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA PCAC notice |
| Thymosin Alpha-1 FDA's safety-risk page discusses thymosin-alpha 1 and says available safety information is inadequate for compounded-use conclusions. | Thymalfasin | FDA safety-risk page | Safety-risk signal | High | ImmuneInfectious disease research | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA safety-risk page |
| GHK-Cu FDA's May 2026 503A update added non-injectable GHK-Cu back to Category 1 while injectable GHK-Cu remains a safety-risk signal. | Copper tripeptide-1 | Route-specific 503A signal | Route-specific | High | Skin and hairLongevity | Cosmetic/research framing varies by product claim | Cosmetic/research framing varies by product claim | 2026-05-28 | FDA 503A category PDF |
| MOTS-c FDA discusses MOTs-C on its safety-risk page and scheduled MOTs-C-related substances for PCAC review. | Mitochondrial open reading frame peptide | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High | MetabolicLongevity | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA PCAC notice |
| Epitalon FDA discusses epitalon on its safety-risk page and scheduled epitalon-related substances for PCAC review. | Epithalon tetrapeptide | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High | LongevitySleep | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA PCAC notice |
| Melanotan II FDA's safety-risk page discusses melanotan II and cites serious adverse-event case reports. | Melanocortin receptor agonist | FDA safety-risk page | Safety-risk signal | High | Skin and hairSexual health | Unlicensed medicine; enforcement history around tanning products | Restricted; not approved for tanning use | 2026-05-28 | FDA safety-risk page |
| PT-141 Bremelanotide has an FDA-approved drug form, but that does not automatically resolve broader compounded or research-product sourcing questions. | Bremelanotide | FDA-approved drug context | Approved-drug context | Medium | Sexual health | Prescription medicine context where supplied | Prescription-only context where supplied | 2026-05-28 | FDA compounding overview |
| DSIP FDA discusses emideltide/DSIP on its safety-risk page and scheduled DSIP-related substances for PCAC review. | Delta sleep-inducing peptide | Safety-risk page; PCAC review scheduled | PCAC review July 2026 | High | SleepCognitive | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA PCAC notice |
| Sermorelin Sermorelin remains relevant to growth-hormone-releasing peptide research, but it was not confirmed in the current FDA source set used for this watchlist update. | GRF 1-29 | No current 503A peptide signal confirmed in reviewed FDA sources | Monitor | Low | Growth hormoneBody composition | Research chemical; not licensed as a medicine | Unapproved/prescription context depends on product claim and access pathway | 2026-05-28 | FDA compounding overview |
| Tesamorelin Tesamorelin has an established pharmaceutical context, but compounded or research-product sourcing remains a separate regulatory question. | Growth hormone releasing factor analog | FDA-approved drug context | Approved-drug context | Medium | MetabolicBody composition | Prescription medicine context where supplied | Prescription-only context where supplied | 2026-05-28 | FDA compounding overview |
| Hexarelin Hexarelin is a growth-hormone secretagogue of anti-doping concern, but it was not confirmed in the current FDA source set used for this watchlist update. | Growth hormone secretagogue | No current 503A peptide signal confirmed in reviewed FDA sources | Monitor | Low | Growth hormoneRecovery | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA compounding overview |
| GHRP-2 FDA's May 2026 503A PDF lists GHRP-2 in Category 3, while FDA's safety-risk page lists GHRP-2 for injectable and nasal routes under 503B Category 2. | Growth hormone releasing peptide-2 | 503A Category 3; 503B Category 2 safety-risk signal | Category 3 | High | Growth hormoneBody composition | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA 503A category PDF |
| GHRP-6 FDA's May 2026 503A PDF lists GHRP-6 in Category 3, while FDA's safety-risk page lists GHRP-6 under 503B Category 2. | Growth hormone releasing peptide-6 | 503A Category 3; 503B Category 2 safety-risk signal | Category 3 | High | Growth hormoneAppetite | Research chemical; not licensed as a medicine | Not listed; supply claims require case-by-case review | 2026-05-28 | FDA 503A category PDF |